The complex role of PD-L1 in antitumor immunity: a recent update
- 31 May 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (8), 2067-2068
- https://doi.org/10.1038/s41423-021-00702-y
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81971467)
This publication has 16 references indexed in Scilit:
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regressionJCI Insight, 2018
- The host protecting the tumor from the host — targeting PD‑L1 expressed by host cellsJCI Insight, 2018
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicityThe Journal of Experimental Medicine, 2017
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapyOncoImmunology, 2017
- Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune EscapeCancer Immunology Research, 2017
- The clinical utility of PD‐L1 testing in selecting non‐small cell lung cancer patients for PD1/PD‐L1‐directed therapyClinical Pharmacology & Therapeutics, 2016
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia StudyJournal of Clinical Oncology, 2016
- PD-1/PD-L1 inhibitorsCurrent Opinion in Pharmacology, 2015
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2002